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Abstract 
To investigate the protective effects  and the possible mechanisms of  garlic oil (GO)  against 
N-nitrosodiethylamine (NDEA)-induced hepatocarcinoma in rats, Wistar rats were gavaged with 
GO (20 or 40 mg/kg) for 1 week, and then were gavaged with GO and NDEA (10 mg/kg) for the 
next 20 weeks. The changes of morphology, histology, the biochemical indices of serum, and DNA 
oxidative damage of liver were examined to assess the protective effects. Lipid peroxidation 
(LPO), antioxidant defense system, and apoptosis-related proteins were measured to investigate 
potential mechanisms. At the end of the study (21 weeks), GO administration significantly inhibited 
the increase of the nodule incidence and average nodule number per nodule-bearing liver induced 
by NDEA, improved hepatocellular architecture, and dramatically inhibited NDEA-induced ele-
vation of serum biochemical indices (alanine aminotransferase , aspartate aminotransferase, alka-
line phosphatase and gamma-glutamyl transpeptidase) and hepatic 8-hydroxy-2’-deoxyguanosine 
(8-OHdG) levels in a dose-dependent manner. The mechanistic studies demonstrated that GO 
counteracted NDEA-induced oxidative stress in rats illustrated by the restoration of glutathione 
(GSH), superoxide dismutase (SOD), catalase (CAT), glutathione reductase (GR), glutathione 
peroxidase (GPx), glutathione-S-transferase (GST) levels, and the reduction of the malondialde-
hyde (MDA) levels in liver. Furthermore, the mRNA and protein levels of Bcl-2, Bcl-xl, andβ
-arrestin-2 were significantly decreased whereas those of Bax and caspase-3 were significantly 
increased. These data suggest that GO exhibited significant protection against NDEA-induced 
hepatocarcinogenesis, which might be related with the enhancement of the antioxidant activity and 
the induction of apoptosis. 
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Introduction 
Liver cancer is the second most frequent cause of 
death in 2010 throughout the world [1]. Exposure to 
environmental  carcinogens  is  an  important  factor 
leading  to  the  formation  of  hepatocarcinoma. 
N-nitrosodiethylamine  (NDEA),  which  exists  wide-
spreadly in nature such as  in cheese, soybean, pro-
cessed meats, alcoholic beverages, tobacco products, 
cosmetics  and  agricultural  chemicals,  is  one  of  the 
most  important  environmental  carcinogens  [2-4]. 
NDEA can induce carcinoma in all animal species as 
well as humans [5], and has been used as an experi-
mental carcinogen in many studies. 
The  conventional  therapy  of  hepatocarcinoma 
including chemotherapy, radiation, surgical resection 
and ablation gives little hope for restoration of health 
because  of  poor  diagnosis  and  serious  side  effects. 
Liver  transplantation  is  considered  to  be  the  most 
effective treatment for patients with hepatocarcinoma. 
However, low availability of organs limits the offer of 
this option to all candidates, and the high risk of tu-
mor  recurrence  after  transplantation  further  com-
promises  its  efficiency  [6].  Therefore,  developing 
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more  effective  and  less  toxic  anti-cancer  agents,  in-
cluding natural products, is necessary to prevent or 
retard the process of hepatocarcinogenesis. 
Garlic  (Allium  sativum)  is  cultivated  and  con-
sumed worldwide. The application of garlic for me-
dicinal purposes can be dated back to antiquity. Pre-
vious studies have shown that garlic possesses many 
biological activities, such as antimicrobial, antiather-
osclerotic,  antihypertensive,  immunomodulation, 
radioprotection and anticancer  [7-10]. Multiple lines 
of experimental and clinical evidence  suggested the 
organosulfur  compounds  (OSCs)  originating  from 
garlic, accounting for only 1% of garlic weight, are the 
main anti-cancer active constituents [9, 11-13], and the 
variability in composition of OSCs influences the bi-
ological  properties  of  garlic  [14-15].  Currently,  the 
steam  distillation  method  is  widely  used  to  extract 
and condense volatile OSCs from garlic and the final 
oily product is called garlic oil (GO), which contains 
more than 30 OSCs [16]. It has been reported that di-
allyl sulfide (DAS), diallyl disulfide (DADS) and di-
allyl trisulfide (DATS) are the three major components 
involved in GO [17]. In contrast with the numerous 
studies on the pharmacological investigations about 
GO, fewer studies have been conducted with regard 
to its bioavailability. However, several studies have 
determined the metabolites of the above three diallyl 
sulfides in the breath of the volunteers as well as in 
different organs of rats [18-19]. It could be speculated 
that GO may have good bioavailability in humans. 
Previous  studies  also  indicated  that  GO  could 
reduce cancer risk including gastric carcinoma, kid-
ney cancer, skin tumor [20-22], however, the role of 
GO against NDEA-induced hepatocarcinoma remains 
unclear. 
Accumulating  evidence  has  demonstrated  that 
overproduction  of  reactive  oxygen  species  (ROS) 
plays a key role in the etiology of hepatocarcinoma. 
ROS could result in oxidative damage of DNA, which 
facilitating the formation of hepatocellular carcinomas 
[23]. Besides, dysregulated apoptosis was related to 
hepatocarcinogenesis  induced  by  many  chemicals 
including  NDEA  [24].  As  GO  has  excellent  antioxi-
dant capacity [23, 25] and the constituents of GO have 
proapoptotic  activities  in  many  cancer  cell 
lines[26-28], it is interesting to examine whether or not 
GO could inhibit NDEA-induced hepatocarcinogene-
sis by antioxidant capacity and proapoptosis. 
Materials and Methods 
Materials 
GO (drug grade) was purchased from Xuchang 
Yuanhua Biotechnology, Inc. (Xuchang, CN). NDEA 
was  obtained  from  Sigma  Chemical  Co.  (St.  Louis, 
MO,  USA).  DNeasy  tissue  kit  was  obtained  from 
Promega  Corporation  (Madison,  WI,  USA). 
8-hydroxy-2’-deoxyguanosine  (8-OHdG)  ELISA  kit 
was provided by Cell Biolabs, Inc. (San Diego, CA, 
USA). BCATM protein assay kits were purchased from 
Pierce  Biotechnology,  Inc.  (Rockford,  IL,  USA). 
Commercial antioxidantion assay kits for malondial-
dehyde  (MDA),  glutathione  (GSH),  superoxide  dis-
mutase (SOD), glutathione peroxidase (GPx), catalase 
(CAT), and glutathione reductase (GR) were bought 
from  Nanjing  Jiancheng  Bioengineering  Insititute 
(Nanjing, CN).  All antibodies were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Animals and treatments 
60 Male Wistar rats, weighing 120 – 140 g, were 
provided by Laboratory Animal Center of Shandong 
University. All animals received professional humane 
care in compliance with the guidelines of the Ethical 
Committee  of  School  of  Public  Health,  Shandong 
University, China. Rats were housed individually and 
a standard laboratory diet and water were available 
ad libitum. The animal room was maintained at con-
stant temperature of 23 ± 1 ℃ and 50% relative hu-
midity with a 12 h (7:00-19:00) light/dark cycle. After 
1 week on basal diet, the animals were randomly di-
vided into 4 groups (n=15). Rats in GO groups were 
pretreated with GO (20 or 40 mg/kg bw) by gavage 
for 7 days, while the rats in the control and NDEA 
groups received equal volume of corn oil. Then, all the 
animals except those in control group orally received 
NDEA (10 mg/kg bw, 5 time/week) for consecutive 
20 weeks, and the rats in GO groups were continu-
ously administered with GO until the end of the ex-
periment.  The  body  weight  was  measured  weekly, 
and  the  dosage  was  varied  accordingly.  After  20 
weeks  of  NDEA  administration,  all  rats  were  anes-
thetized at 24 hours after the last treatment. Blood was 
collected by cervical decapitation and centrifuged at 1 
500 g for 20 minutes at 4 ℃ to obtain serum. Liver 
tissue was excised, weighed. The amount of nodules 
on  the  liver  surface  was  counted.  A  portion  of  the 
liver was fixed in paraformaldehyde (4%) for histo-
pathological analysis. The other portion of liver tissue 
was quickly frozen in liquid nitrogen before storing at 
-80 ℃. 
Liver morphology and histology 
The amount of nodules in liver was counted by 3 
mm cross-sections, and the nodule incidence and av-
erage nodule number per nodule-bearing liver in all 
groups were calculated. For histological examination, 
about 5 μm paraffin-embedded specimens were pre-Int. J. Biol. Sci. 2012, 8 
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pared,  deparaffinized,  rehydrated,  stained  with  he-
matoxylin  and  eosin  (H&E),  and  viewed  using  an 
Olympus AX70 microscope (Olympus, Tokyo, Japan) 
Serum biochemical assays 
The  levels  of  serum  alanine  aminotransferase 
(ALT),  aspartate  aminotransferase  (AST),  gam-
ma-glutamyl  transpeptidase  (GGT),  alkaline  phos-
phatase  (ALP),  albumin  (ALB),  globulin  (GLB)  and 
total  protein  (TP)  were  determined  using  an  auto-
matic biochemical analyser (BTS-370, BioSystems S.A., 
Barcelona, Spain) according to the instructions sup-
plied  with  the  commercial  assay  kits  (Roche,  Swit-
zerland). 
Quantification of 8-OHdG levels in liver DNA 
by competitive ELISA 
Genomic DNA in liver was extracted from fro-
zen tissues using a DNeasy tissue kit. The 8-OHdG 
levels in liver DNA were determined using an ELISA 
kit.  Briefly,  the  8-OHdG  antibody  and  the  sample 
were added to ELISA plate which had been precoated 
with 8-OHdG. The 8-OHdG in the sample competed 
with the 8-OHdG bond on the plate for the 8-OHdG 
antibody binding sites. The average concentration of 
8-OHdG per microgram of DNA for each group was 
calculated for each sample. Sample DNA assays were 
performed in duplicate. 
Antioxidant status in liver 
The liver tissue was homogenized in 9 volumes 
of ice-cold buffer (pH 7.4) containing 0.01 M Tris-HCl, 
0.1 mM EDTA-2Na, 0.01 M saccharose, and 0.8% sa-
line.  The  homogenates  were  centrifuged  at  1000×g 
for 20 min at 4℃. The supernatant was collected, ali-
quoted, and stored at -80℃ for antioxidant assay. 
LPO  was  determined  by  measuring  the  accu-
mulation of thiobarbituric acid-reactive substance and 
expressed as MDA content. The levels of MDA, GSH 
and  the  activities  of  antioxidant  enzymes  including 
SOD, CAT, GR, GPx, and GST, were assayed using 
commercial assay kits according to the manufacturer’s 
instructions. The MDA and GSH level was expressed 
as nmol/mg protein and mg/g protein, respectively. 
The activities of antioxidant enzymes were expressed 
as U/mg protein or U/g protein. 
Western blotting analysis 
The protein samples were extracted and western 
blotting  was  performed  as  we  previously 
reported[29].  Briefly,  the  liver  tissue  was  homoge-
nized in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 
1% Triton X-100, 1% sodium deoxychlolate, 0.1% so-
dium dodecylsulphate, 50 mM β-glycerophosphate, 
1 mM Na3VO4, 5 mM NaF, 1 % cocktail protein inhib-
itors and 1 mM phenylmethylsulfphonylfloride), then 
were centrifuged at 14 000g for 15 min. The protein 
extracts (20-50 μg) were separated on 12% or 15% SDS 
(sodium  dodecyl  sulfate,  SDS)-polyacrylamide  gels, 
transferred to polyvinylidene fluoride (PVDF) mem-
branes,  incubated  with  primary  antibodies  (Bcl-2, 
Bcl-xl,  β-arrestin-2,  Bax,  cleaved  Caspase-3  and  β
-actin) and the corresponding horseradish peroxidase 
conjugated  secondary  antibodies.  The  signals  were 
detected by enhanced chemiluminescence kit (Pierce, 
Rockford, IL, USA) and the relative optical densities 
of the bands were quantified using Kodak Imaging 
Program and Image-Pro Plus software. 
RNA extraction and cDNA synthesis 
Total RNA was isolated from the rat livers using 
Trizol reagent (Invitrogen Corp., Carlsbad, CA, USA) 
according to the manufacture’s instructions. The RNA 
pellet was dissolved in DEPC water. The concentra-
tion and integrity of total RNA was measured using a 
Nanodrop  spectrophotometer  (Nanodrop  2000c, 
Thermo Scientific, Wilmington, DE, USA) and Agilent 
2100 Bioanalyzer (Agilent Technologies, Waldbronn, 
Germany).  Complementary  DNA  was  synthesized 
using the RevertAid TM First Strand cDNA Synthesis 
Kit (Fermentas) according to the manufacture’s pro-
tocol. 
Real-time PCR analysis 
The levels of gene expression in liver tissue were 
quantified by real-time PCR. The primers were syn-
thesized by Sangon Biotech Co., Ltd (Shanghai, CN) 
(Table  1).  All  PCR  reactions  were  performed  using 
Maxima SYBR Green qPCR Master Mix (Fermentas) 
and were carried out under the following conditions 
using MasterCycler  TM eppendorf realplex 4 (Eppen-
dorf, Westbury, NY, USA): initial denaturation at 95 
℃ for 10 min followed by 40 cycles of 15 s at 95 ℃, 30 s 
at 60 ℃ and 30 s at 72 ℃. Each sample was analyzed in 
triplicate.  Differences  in  gene  expression  between 
groups were calculated using the △△Ct (cycle time, 
Ct)  method  [30],  which  were  normalized  against 
glyceraldehydes-3-phosphate  dehydrogenase 
(GAPDH)  and  expressed  as  relative  mRNA  levels 
compared with controls. 
Statistical analysis                                   
 SPSS13.0  was  used  for  the  statistical  analysis. 
The  Chi-Square  test  was  used  for  nodule  incidence 
analysis. Other data were expressed as mean ± SD, 
and  were  analyzed  by  one-way  ANOVA,  followed 
with Tukey for the multiple comparisons. Differences 
were considered significantly at P < 0.05 level. Int. J. Biol. Sci. 2012, 8 
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Results 
Changes of body weight and relative liver 
weight 
 Figure 1 summarizes the effect of GO on body 
weight  changes  induced  by  NDEA.  On  first  week 
following NDEA treatment, the rats began to show a 
slow  growth.  Along  with  the  NDEA  exposure,  the 
mean  weight  gain  decreased  gradually.  After  14 
weeks of exposure, the body weight in NDEA group 
showed negative growth. At the end of 21 weeks, the 
body weight of rats in control group was increased to 
about 2.62-fold of the initial value, while that of rats in 
NDEA group was only about 1.46-fold. In contrast, 
GO treatment significantly recovered the body weight 
gain  of  rats  (1.86-fold  and  2.06-fold  in  20  and  40 
mg/kg  group,  respectively),  compared  to  that  in 
NDEA group (Figure 1). 
Table 2 shows the final body weight and liver 
weight of different groups of rats. The relative liver 
weight in NDEA group was increased compared with 
that in control group (P<0.01). Administration of 20 
and 40 mg/kg GO significantly reduced the relative 
liver  weight  as  compared  with  NDEA  group  (P  < 
0.01). 
 
 
Figure 1. Changes of rat body weight. The data of body weight were presented as mean ± S.D. Statistical difference was 
shown as: *P < 0.05, **P < 0.01, with respect to control; 
# P < 0.05, 
##P < 0.01, with respect to NDEA group. 
 
Table 1. Sequences of primers used for the Real-time PCR analysis. 
Gene symbol  Forward primer  Reverse primer 
Bcl-2   CCCCAGAAGAAACTGAACC  GCATCTCCTTGTCTACGC 
Bcl-XL  GCCACAAAGAAACCAATTCTG  CCGGTTGCTCTGAGACATTT 
β-arrestin-2  CCACGTCACCAACAATTCTG  TTGGTGTCTTCGTGCTTGAG 
Bax  GTTGCCCTCT TCTACTTTGC  ATGGTCACTG TCTGCCATG 
Caspase-3  CTGGACTGCGGTATTGAGAC  CCGGGTGCGGTAGAGTAAGC 
GAPDH  TCAAGAAGGTGGTGAAGCAG  AGGTGGAAGAATGGGAGTTG 
 
 
Table 2. Body and liver weights of different groups of rats at the end of the study (mean±S.D.). 
Groups  Final body weights (g)  Liver weights (g)  Relative liver weight 
(g liver/100g body weight) 
control  500±32  14.98±1.33  3.006±0.334 
NDEA+GO(low )  398±39*#  16.59±5.46##  4.242±1.673## 
NDEA+GO(high)  413±44*##  15.45±4.50##  3.709±1.204## 
NDEA  327±49**  25.38±7.52**  7.861±2.360** 
Compared with control, *P < 0.05, **P < 0.01; compared with NDEA group, #P < 0.05, ##P < 0.01. 
 Int. J. Biol. Sci. 2012, 8 
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Morphological and histological changes of the 
liver 
The appearance of livers in control group was 
normal  and  no  macroscopically  detectable  nodules. 
The rats in NDEA group revealed enlarged liver, and 
the nodule incidence of NDEA group was 100% and 
the maximum diameter of nodules was about 10mm. 
At the same time, there were clear necrosis regions in 
livers  of  NDEA-treated  rats.  Interestingly,  a  signifi-
cant reduction in liver enlargement, nodule incidence 
and average nodule numbers per nodule-bearing liver 
was observed in GO-treated rats compared with that 
of NDEA group (Fig. 2A and Fig. 2C).  
Representative histology photos of the liver in all 
groups were depicted in Fig. 2B. The livers of control 
group showed normal liver and hepatocyte architec-
ture. The hepatocellular architecture in NDEA group 
was  completely  destroyed,  with  many  hyperplastic 
nodules  and  obvious  heteromorphism.  The  nuclei 
were prominent and occupied most of the cells. These 
histopathological features were greatly reduced in the 
liver  of  rats  treated  with  GO.  Again,  the  histology 
analysis in GO group (40 mg/kg) showed significant 
improvement  of  hepatocellular  architecture  as  com-
pared with NDEA group. 
Serum biochemical assays.  
The serum ALT, AST, ALP, and GGT levels were 
elevated  in  NDEA  group  compared  with  those  in 
control group (P < 0.01), which indicating liver dam-
age and preneoplastic lesion. The serum albumin was 
decreased,  while  globulin  was  increased  in  NDEA 
group compared with those in control group. There-
fore, the A/G ratio was declined by NDEA treatment. 
All  the  above  adverse  effects  of  NDEA  were  sup-
pressed by GO (Table 3).  
GO inhibited the formation of 8-OHdG in liver 
DNA induced by NDEA 
As shown in Figure 3, after 21 weeks of NDEA 
treatment, the content of 8-OHdG was augmented to 
2.41-fold  (P  <  0.01)  compared  with  that  in  control 
group. 
However, this elevation of 8-OHdG induced by 
NDEA  was  significantly  reduced  in  GO-treated 
groups  and  decreased  by  29%  (P<0.05)  and  44% 
(P<0.01) in 20 mg/kg and 40 mg/kg groups, respec-
tively. 
 
 
Figure 2. Effect of GO on hepatic morphology and histology in NDEA-intoxicated rats. A: The gross appearance of liver. B: 
Representative photomicrographs of hepatic histology changes in 4 groups (HE staining, ×200). C: Changes of nodule 
incidence and average number of nodules per nodule-bearing liver in rats. 
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Table 3. Changes of biochemical parameters in serum (mean±S.D.).  
Groups  ALT(U/L)  AST(U/L)  ALP(U/L)  GGT(U/L)  TP(g/L)  ALB(g/L)  GLB(g/L)  A/G 
Control  66±11  188±27  138±25  1.1±0.7  77.9±4.1  40.3±3.7  37.6±4.9  1.08±0.10 
NDEA+GO(low)  118±33**##  232±39**##  248±36  24.4±11.5  83.4±3.0  39.2±1.5  44.2±5.9*  0.91±0.08*# 
NDEA+GO(high)  109±18**##  226±31##  227±63##  20.3±12.3##  84.0±3.8*  41.2±3.9  42.8±4.3#  0.98±0.11## 
NDEA  186±39**  388±58**  362±61**  120.2±37.7**  84.8±3.5*  37.8±2.7*  47.1±4.7**  0.82±0.12** 
*P<0.05, **P<0.01, compared with control group; #P<0.05, ##P<0.01, compared with NDEA group. 
 
 
 
Figure 3. The content of 8-OHdG in liver DNA. The data was presented as mean ± S.D. *P<0.05, **P<0.01, compared with 
control group; 
#P<0.05, 
##P<0.01, compared with NDEA group. 
 
Changes of lipid peroxidation and antioxida-
tive status 
 Considering the key roles of ROS in the devel-
opment  of  NDEA-induced  hepatocarcinoma,  it  was 
necessary and important to investigate the changes of 
the hepatic antioxidant system, which were displayed 
in Table 4. 
NDEA  significantly  increased  the  MDA  level, 
which  was  markedly  suppressed  by  GO  treatment. 
Compared with that of NDEA group, the MDA level 
was decreased by 34% and 44% (P<0.01) in 20 mg/kg 
and 40 mg/kg GO groups, respectively. No signifi-
cant difference of MDA level was observed between 
GO  and  control  groups  (P  >  0.05).  Furthermore, 
NDEA  caused  significant  decreases  in  the  level  of 
GSH, and impaired the activities of SOD, GR, GST, 
CAT and GPx. Compared with NDEA group, 20 and 
40 mg/kg GO significantly increased the hepatic level 
of GSH and the activities of SOD, GR, GST, CAT and 
GPx by 143%, 17%, 47%, 43%, 27%, 75% and 636%, 
24%, 79%,54%, 34%, 94% (P < 0.01), respectively. The 
high dose of GO inhibited NDEA-induced oxidative 
stress more effectively than the low dose of GO. 
GO accelerated apoptosis in liver of 
NDEA-induced rats. 
Because  dysregulation  of  apoptosis  is  an  im-
portant cause for the hepatocarcinoma formation [31], 
we  further  investigated  the  mRNA  and  protein  ex-
pression levels of the apoptosis-related proteins. 
As shown in Figure 4 and Figure 5, quantitative 
real-time PCR and Western blotting results showed 
significant increases in mRNA and protein expression 
levels  of  anti-apoptotic  Bcl-2  and  Bcl-xl  in  NDEA 
group, as compared with the control group (P<0.05). 
Similarly significant decreases in Bax and Caspase-3 
mRNA and protein expression levels were noticed in 
NDEA  group.  Therefore,  the  Bcl-2/Bax  ratio  re-
mained significantly higher in NDEA group than that 
in  control  group.  In  contrast,  GO  administration 
markedly  suppressed  the  expressions  of  Bcl-2  and 
Bcl-xl  and  increased  the  expressions  of  Bax  and 
Caspase-3. Interestingly, the Bcl-2/Bax ratio was sig-
nificantly  decreased  in  GO  groups  compared  with 
that in NDEA group. 
Changes in β-arrestin-2 expression following 
treatment with GO in NDEA-induced hepa-
tocarcinoma in rats 
Recently,  β-arrestin-2  was  shown  to  mediate 
anti-apoptotic  signaling,  so  we  detected  the  expres-
sion  levels  of  β -arrestin-2  in  liver  tissues.  β
-arrestin-2 mRNA and protein levels showed signifi-
cant increases in NDEA-treatment rats compared with 
those in control rats (P<0.01). Treatment with GO in-
hibited the increases of β-arrestin-2 mRNA and pro-
tein levels induced by NDEA (P<0.01). Int. J. Biol. Sci. 2012, 8 
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Table 4.  Changes of lipid peroxidation and antioxidative status in liver homogenates (mean±S.D.).  
Groups  MDA  
(nmol/mg prot) 
GSH 
 (mg/g prot) 
SOD  
(U/mg prot) 
GR 
 (U/g prot) 
GST 
 (U/mg prot) 
CAT  
(U/mg prot) 
GPx  
(U/mg prot) 
control  0.84±0.13  16.31±3.00  111.54±4.15  11.52±1.98  22.88±2.13  43.08±4.79  651.65±59.20 
NDEA+ 
GO(low) 
0.99±0.26##  2.43±0.88** ##  104.04±15.86##  7.43±1.25* #  18.12±2.72** ##  22.80±3.91**#  550.95±93.26*## 
NDEA+ 
GO(high) 
0.94±0.11##  7.36±1.97* ##  109.96±13.80##  9.05±1.76##  19.54±3.63** ##  24.19±3.58**##  610.82±97.77## 
NDEA  1.51±0.36**  1.00±0.43**  88.69±10.51**  5.07±1.03**  12.69±2.67**  18.01±3.47**  315.33±73.75** 
*P<0.05, **P<0.01, compared with control group; #P<0.05, ##P<0.01, compared with NDEA group. 
 
 
 
Figure 4. Effect of GO and NDEA on the mRNA level of Bcl-2, Bcl-XL, Bax and Caspase-3. The mRNA levels 
were quantified with GAPDH as an internal control. The control group was defined as 100%. *P<0.05, **P<0.01, compared 
with control group; 
#P<0.05, 
##P<0.01, compared with NDEA group. 
 
Figure 5. Effect of GO and NDEA on the protein level of Bcl-2, Bcl-XL, Bax and Caspase-3. A: A representative 
immunoblot. B: Data presented the expression of Bcl-2, Bcl-XL, Bax and Caspase-3 as percentage of control group (mean ± 
SD) in triplicate. The protein levels were quantified with β-actin as an internal control. *P<0.05, **P<0.01, compared with 
control group; 
#P<0.05, 
##P<0.01, compared with NDEA group. (lane 1) control; (lane 2) NDEA+GO (low); (lane 3) 
NDEA+GO (high); (lane 4) NDEA. Int. J. Biol. Sci. 2012, 8 
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Figure 6. Effect of GO and NDEA on the mRNA and protein levels of β-arrestin-2. The protein levels were 
quantified with β-actin as an internal control. The mRNA levels were quantified with GAPDH as an internal control. *P<0.05, 
**P<0.01, compared with control group; 
#P<0.05, 
##P<0.01, compared with NDEA group. 
 
Discussion 
In this study, GO (20 or 40 mg/kg) was demon-
strated to significantly reduce the numbers and sizes 
of the tumor nodules, improve the histopathological 
damages and serum biochemical indices, and inhibit 
the  DNA  damage  induced  by  NDEA.  We  further 
found  that  GO  dose-dependently  activated  the  he-
patic antioxidant system and regulated the apoptot-
ic-related proteins. These results provided strong ev-
idence that GO significantly prevented the develop-
ment of NDEA-induced hepatocarcinoma. 
GO administration (20 or 40 mg/kg) resulted in 
fewer  rats  developing  visible  nodules  and  smaller 
nodule  number  per  nodule-bearing  rat  liver  than 
those observed in NDEA group rats. GO also signifi-
cantly inhibited the NDEA-induced liver weight in-
creases.  The  hepatic  histopathological  damage  in-
duced  by  NDEA  was  improved  in  GO-treated  rats. 
Because the correlation of the number of hyperplastic 
nodules  and  hepatocarcinoma  in  experimental  and 
human disease [32], the inhibition of nodule growth 
by GO in our experiment was important for hepato-
carcinoma prevention. 
The activities of ALT, AST and ALP in serum are 
generally accepted as indices of liver injury and this 
tendency is also known to be distinct in rodents[33]. 
The serum GGT activity is considered to biomarker of 
preneoplastic  lesion.  These  enzymatic  activities  ele-
vation may potentially be attributed to the release of 
these  enzymes  from  the  cytoplasm  into  the  blood 
circulation after liver cellular damage [34]. Therefore, 
we  first  detected  the  changes  of  these  marker  en-
zymes.  The  results  of  our  study  showed  a  sharply 
inhibitory  effect  of  GO  on  the  enzymatic  activities 
increase initiated by NDEA, which indicated that GO 
could  suppress  NDEA-induced  liver  damage.  As 
there  is  a  close  connection  between  GGT  activation 
and carcinogenesis, the increase of GGT activity could 
be correlated with a high nodule incidence and nod-
ule number. 
Liver is the main site of NDEA metabolism, the 
generation  of  ROS  in  the  liver  is  recognized  as  an 
important contributor in NDEA-induced carcinogenic 
effects [34]. ROS are continuously generated in vivo as 
a  result  of  NDEA  administration  causing  oxidative 
stress that seriously damaged the biological systems 
by injuring tissues, altering biochemical compounds, 
causing chromosomal instability, eroding cell mem-
branes and mutation, which are involved in all steps 
of carcinogenesis, i.e. initiation, promotion and pro-
gression  [35].  LPO  is  a  useful  marker  of  oxidative 
stress because it is correlated with increased produc-
tion of ROS [36], and plays an important role in car-
cinogenesis  induced  by  NDEA  [37].  MDA  has  long 
been  used  as  a  particular  biomarker  of  oxidative 
damage and LPO, and the increase of MDA reflects 
the enhancement of the LPO [38]. In the present study, 
we found that the level of MDA was significantly el-
evated by NDEA. However, the rats pretreated with 
GO  displayed  a  manifest  reduction  in  the  level  of 
MDA compared with that in NDEA group. The ob-
served reduction in the level of LPO in GO-treated 
animals was presumably due to the increase of anti-
oxidative capabilities. Int. J. Biol. Sci. 2012, 8 
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For the purpose of preventing cellular damage 
induced by ROS, the organism has a lot of antioxida-
tive  defense  system,  including  the  non-enzymatic 
(mainly  GSH)  and  enzymatic  antioxidant  defenses 
(including SOD, GR, GST, CAT and GPx). GSH plays 
an important role in maintaining the normal reduced 
state of cells and counteracting the harmful effects of 
oxidative  stress  [39].  GSH  can  effectively  scavenge 
free radicals and other oxygen species through non-
enzymatic and enzymatic process by conjugation with 
GPx  and  GST  [40].  GPx  ubiquitously  exists  both  in 
cytosol  and  mitochondria  of  the  hepatocytes.  GST 
locates in cytosol and plays an important role in de-
toxification  and  excretion  of  xenobiotics  [41].  GST 
catalyzes  the  conjugation  of  the  thiol  functional 
groups of GSH to electrophilic xenobiotics, leading to 
elimination  or  conversion  of  xenobiotic-GSH  conju-
gate [42]. In such reaction, the GSH is oxidized into 
GSSG, which can be reduced to GSH by GR with the 
consumption of NADPH [43]. In addition, GSH can 
also  react  with  various  electrophiles,  physiological 
metabolites  and  xenobiotics  to  form  mercapturates, 
which  are  catalyzed  by  glutathione  S-transferase 
(GST)  [44-45].  In  addition  to  GSH  and  GSH-related 
antioxidant enzymes, other antioxidant enzymes in-
cluding SOD and CAT also take important role in the 
antioxidant  defense  system.  SOD  can  catalyze  the 
dismutation of two superoxide radicals to H2O2 and 
O2. CAT acts as supporting antioxidant enzymes by 
transforming H2O2 to H2O, thereby providing protec-
tion against ROS [36].  
Banerjee et al. (2002) reported that garlic had a 
powerful  antioxidative  defense  system  and  mini-
mized intracellular oxidative stress. Among various 
garlic components, the OSCs are considered as main 
bioactive components. Wu et al. reported GO, DADS 
and  DATS  but  not  DAS  significantly  increased  the 
activities of GST and GSH reductase [16]. Our previ-
ous study also showed that administration of DATS 
(one of the components of GO) significantly decreased 
LPO and increased the activities of endogenous anti-
oxidants, such as SOD, CAT, GPx [44]. In the present 
study, NDEA resulted in significant decreases in the 
level of  GSH and the activities  of  antioxidation en-
zymes including GR, GPx and GST. The reduction in 
the activities of these enzymes may be resulted from 
excessive LPO during NDEA metabolism. However, 
the effects of NDEA were partially counteracted by 
GO, which suggests that the elevation of GSH might 
be one of the important mechanisms for GO against 
NDEA-induced hepatocarcinoma 
Oxidative  DNA  damage  maybe  an  important 
underlying event that leads to cancer [46]. Cherng etal 
found that DAS, one of the principal components of 
GO,  protected  against  ultraviolet  B-induced  skin 
cancers in SKH-1 hairless mouse by preventing DNA 
damage and facilitating DNA repair [47]. To further 
evaluate the roles of GO against NDEA-induced de-
volvement of hepatocarcinoma, we examined the lev-
els of 8-OHdG, a DNA base-modified product gener-
ated  by  reactive  oxygen  species,  which  is  a  good 
marker  for  DNA  oxidative  damage  due  to  aging, 
cancer and other degenerative diseases [48]. The data 
clearly showed that GO administration significantly 
decreased the levels of 8-OHdG in liver DNA com-
pared with that in NDEA group, which suggested that 
GO could significantly prevent NDEA-induced DNA 
damage. 
Tumor initiation, progression, and maintenance 
commonly  involve  alterations  in  apoptosis.  Studies 
have  shown  that  dysregulation  of  apoptosis  is  an 
important  cause  for  the  hepatocarcinoma  formation 
[31].  Accumulating  data  indicate  that  induction  of 
apoptosis is  a crucial event for chemoprevention of 
cancer  by  naturally  occurring  dietary  agents  [49]. 
Thus, we evaluated the changes of apoptotic-related 
factors in mRNA and protein expression levels. 
The  antiapoptotic  Bcl-2  family  proteins  act  by 
neutralizing proapoptotic proteins and play a pivotal 
role in determining the ability of a cancer cell to un-
dergo  apoptosis  [50].  Bax,  normally  residing  in  the 
cytosol,  translocates  to  mitochondria  to  promote 
apoptosis,  but  Bax  activity  is  counteracted  by 
antiapoptotic proteins, such as Bcl-2 and Bcl-xL [51]. 
Many cancer cells evade apoptosis by up-regulation 
of the expressions of Bcl-2 and Bcl-xL [52-53]. In the 
present study, GO up-regulated the expression of Bax 
and  down-regulated  the  expression  of  Bcl-2  and 
Bcl-xL,  when  compared  with  NDEA  group.  DATS, 
one of the important components of GO, have been 
proven  to  induce  apoptosis  in  MCF7  human  breast 
cancer cells by decreasing the expression of Bcl-2 and 
enhancing the expression of Bax [54], which is con-
sistent with our experimental results.  
The ratio of Bcl-2 to Bax, rather than the levels of 
the individual proteins, is considered to be critical in 
determining  the  survival/death  of  cells  [55].  De-
creased  Bcl-2/Bax  ratio  will  induce  apoptosis  [56]. 
Our results showed that the ratio of Bcl-2 to Bax was 
prominently  decreased  by  GO  which  may  lead  to 
apoptotic  response  in  hepatocarcinogenesis  induced 
by  NDEA.  Many  researches  also  demonstrated  that 
one of important mechanisms of preventing hepato-
carcinoma is reducing the ratio of Bcl-2/Bax for cap-
saicin, zerumbone, matrine and leptin [57-60]. 
Caspase activation plays a central role in the ex-
ecution of apoptosis. The activation of Caspase-3 is a 
common event in two major pathways, death receptor Int. J. Biol. Sci. 2012, 8 
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and  mitochondrial  pathways  [61-63].  In  the  present 
study, NDEA administration inhibited the expression 
of  Caspase-3,  but  GO  activated  the  expression  of 
Caspase-3. The apoptosis induced by PTX-2 in human 
hepatocellular  carcinoma  cells  was  associated  with 
the  down-regulation  of  Bcl-2  and  Bcl-xL,  the 
up-regulation of Bax and the activation of Caspase-3 
[64].  Therefore,  GO  induced-apoptosis  by 
down-regulation of Bcl-2, Bcl-xL and up-regulation of 
Bax and Caspase-3 could be one of important mecha-
nisms of preventing hepatocarcinoma. 
β-arrestin-2,  originally  discovered  as  termina-
tors of G protein-coupled receptor signaling, has been 
revealed  novel  functions  as  signal  transducers  in 
various  signaling  pathways  [65-66].  Among  these 
processes, β-arrestin-2 has been reported to mediate 
anti-apoptotic  signaling  by  activating  the  intrinsic 
apoptotic pathway [67-68]. Khan et al. first reported 
the changes of β-arrestin-2 expression in neoplastic 
nodules  in  2011  [68].  Our  results  showed  that  β
-arrestin-2  expression  increase  in  NDEA  treatment 
rats may lead to antiapoptotic effect, which correlated 
well  with  the  upregulation  of  Bcl-2,  Bcl-xL  and 
downregulation of Bax and Caspase-3. Reversely, GO 
treatment  led  toβ-arrestin-2  expression  decrease  in 
mRNA and protein levels, thus promoting apoptotic 
signaling as evidenced by the upregulation of Bax and 
Caspase-3. Furthermore, β-arrestin-2 participated in 
the Wnt signaling pathway [69], which is frequently 
imbalanced in hepatocarcinoma. 
Increasing ROS generation is one of the mecha-
nisms of some exogenous chemicals inducing apop-
tosis, and thus antioxidation is theoretically to pro-
duce anti-apoptotic effects. However, some chemicals 
prevented  cancer  by  enhancing  antioxidant  activity 
and  inducing  apoptosis.  For  example,  saffron  and 
polyphenols exert a significant chemopreventive ef-
fect  against  cancer  through  the  antioxidant  activity 
and induction of apoptosis [4, 70]. Therefore, it is not 
paradoxical that GO exhibited potent antioxidant ca-
pacity as well as pro-apoptotic effects. Pre-treatment 
with GO reduced the generation of ROS, but it did not 
inhibit the pro-apoptotic activities of GO, suggesting 
that  multiple  events  overlap  to  explain  the  mecha-
nisms of hepatocarcinoma prevention induced by GO. 
Taken together, the present study is the first to 
demonstrate the in vivo chemoprotective effect of GO 
on  NDEA  induced  hepatocarcinoma.  This  chemo-
protective  effect  of  GO  may  be  associated  with  en-
hancing antioxidant activity and inducing apoptosis. 
Given that there is no effective treatment measure for 
hepatocarcinoma, our findings may suggest a poten-
tial use of GO for hepatocellular carcinoma chemo-
prevention. 
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